title: Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value?
authors.forename: L
authors.initials: L
authors.lastname: Tremolizzo
authors.forename: V
authors.initials: V
authors.lastname: Rodriguez-Menendez
authors.forename: J C
authors.initials: JC
authors.lastname: DiFrancesco
authors.forename: G
authors.initials: G
authors.lastname: Sala
authors.forename: A
authors.initials: A
authors.lastname: Galbussera
authors.forename: I
authors.initials: I
authors.lastname: Appollonio
authors.forename: C
authors.initials: C
authors.lastname: Ferrarese
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D006655:Histone Deacetylases / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology*; D009043:Motor Activity / Q000187:drug effects; D013469:Sulpiride / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid; D013469:Sulpiride; D006655:Histone Deacetylases